Oppenheimer analyst, Ling Wang, believes Relypsa (NASDAQ: RLYP) is undervalued after the acquisition of ZSPH at a value of $2.7B. Competitor ZS-9's interim 52-week data were presented from phase III ZS-005 trial and Wang believes the drugs presented by each company have comparable efficacy. Given the $1.5B valuation gap, the analyst thinks RLYP is undervalued.

The firm reiterated Outperform rating and $55 PT.

For an analyst ratings summary and ratings history on Relypsa, Inc. click here. For more ratings news on Relypsa, Inc. click here.

Shares of Relypsa, Inc. closed at $18.87 yesterday.